CL2019000067A1 - Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. - Google Patents

Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.

Info

Publication number
CL2019000067A1
CL2019000067A1 CL2019000067A CL2019000067A CL2019000067A1 CL 2019000067 A1 CL2019000067 A1 CL 2019000067A1 CL 2019000067 A CL2019000067 A CL 2019000067A CL 2019000067 A CL2019000067 A CL 2019000067A CL 2019000067 A1 CL2019000067 A1 CL 2019000067A1
Authority
CL
Chile
Prior art keywords
antibodies
zika virus
specifically bind
new antibodies
fragments
Prior art date
Application number
CL2019000067A
Other languages
English (en)
Inventor
Davide Corti
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of CL2019000067A1 publication Critical patent/CL2019000067A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

LA INVENCIÓN SE REFIERE A ANTICUERPOS, Y FRAGMENTOS DE UNIÓN A ANTÍGENO DE LOS MISMOS, QUE NEUTRALIZAN POTENTEMENTE LA INFECCIÓN POR EL VIRUS DEL ZIKA (ZIKV). LA INVENCIÓN TAMBIÉN SE REFIERE A LOS SITIOS ANTIGÉNICOS A LOS QUE SE UNEN LOS ANTICUERPOS Y FRAGMENTOS DE UNIÓN A ANTÍGENO, ASÍ COMO A LOS ÁCIDOS NUCLEICOS QUE CODIFICAN E INMORTALIZAN LAS CÉLULAS B QUE PRODUCEN DICHOS ANTICUERPOS Y FRAGMENTOS DE ANTICUERPOS. ADEMÁS, LA INVENCIÓN SE REFIERE AL USO DE LOS ANTICUERPOS Y FRAGMENTOS DE ANTICUERPOS DE LA INVENCIÓN EN MÉTODOS DE ANÁLISIS, ASÍ COMO EN EL DIAGNÓSTICO, PROFILAXIS Y TRATAMIENTO DE LA INFECCIÓN POR ZIKV.
CL2019000067A 2016-07-13 2019-01-09 Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. CL2019000067A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/066684 WO2018010789A1 (en) 2016-07-13 2016-07-13 Novel antibodies specifically binding to zika virus epitopes and uses thereof

Publications (1)

Publication Number Publication Date
CL2019000067A1 true CL2019000067A1 (es) 2019-07-26

Family

ID=56413654

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019000067A CL2019000067A1 (es) 2016-07-13 2019-01-09 Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.
CL2021002994A CL2021002994A1 (es) 2016-07-13 2021-11-12 Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. (divisional de la solicitud no. 201900067)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021002994A CL2021002994A1 (es) 2016-07-13 2021-11-12 Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. (divisional de la solicitud no. 201900067)

Country Status (31)

Country Link
US (3) US11117954B2 (es)
EP (2) EP3484915B1 (es)
JP (2) JP7252888B2 (es)
KR (1) KR102595764B1 (es)
CN (2) CN116199775A (es)
AU (1) AU2017297757A1 (es)
BR (1) BR112018074456A2 (es)
CA (1) CA3024374A1 (es)
CL (2) CL2019000067A1 (es)
CO (1) CO2019001111A2 (es)
CR (1) CR20190066A (es)
DK (1) DK3484915T3 (es)
DO (2) DOP2019000006A (es)
EA (1) EA201990243A1 (es)
EC (1) ECSP19009170A (es)
ES (1) ES2959883T3 (es)
FI (1) FI3484915T3 (es)
HR (1) HRP20231196T1 (es)
HU (1) HUE063272T2 (es)
IL (1) IL262710B1 (es)
LT (1) LT3484915T (es)
MX (1) MX2019000526A (es)
MY (1) MY190553A (es)
PE (1) PE20190398A1 (es)
PH (1) PH12018502348A1 (es)
PL (1) PL3484915T3 (es)
SG (1) SG11201809879WA (es)
SI (1) SI3484915T1 (es)
UA (1) UA126381C2 (es)
WO (2) WO2018010789A1 (es)
ZA (1) ZA201807467B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019000435A2 (pt) 2016-07-13 2019-04-30 Evonik Degussa Gmbh método para separar lipídios de uma biomassa contendo lipídios lisados
WO2018071822A2 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
EP3527664A1 (en) 2018-02-15 2019-08-21 Evonik Degussa GmbH Method of isolating lipids from a lipids containing biomass
JP2019152666A (ja) * 2018-03-02 2019-09-12 富士レビオ株式会社 ジカウイルスを検出する方法及びキット
US11884718B2 (en) 2018-04-24 2024-01-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination
WO2019219443A1 (en) 2018-05-15 2019-11-21 Evonik Operations Gmbh Method of isolating lipids from a lipids containing biomass with aid of hydrophobic silica
WO2020061159A1 (en) * 2018-09-20 2020-03-26 Vanderbilt University Human antibodies to zika virus
WO2020078568A1 (en) 2018-10-19 2020-04-23 Humabs Biomed Sa Antibodies and methods for treatment of lyssavirus infection
BR112021008217A2 (pt) * 2018-10-31 2021-08-17 Icahn School Of Medicine At Mount Sinai anticorpos humanos que têm como alvo vírus zika ns1, polipeptídeos ns1 e seus usos
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
WO2020245663A1 (en) * 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
CN111100201B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体
CN111138534B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 寨卡病毒囊膜蛋白的鼠源单克隆抗体
JP7471555B2 (ja) 2020-02-20 2024-04-22 国立感染症研究所長 フラビウイルス交差中和抗体及び医薬組成物
EP4154003A1 (en) 2020-05-20 2023-03-29 Takeda Vaccines, Inc. Method for determining the potency of antigens
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2021236845A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2022001803A1 (zh) * 2020-06-28 2022-01-06 神州细胞工程有限公司 一种降低病毒ade效应的方法
WO2022212858A2 (en) * 2021-04-01 2022-10-06 A2 Biotherapeutics, Inc. Polypeptides targeting hla-a*11 and methods of use thereof
CN112921124B (zh) * 2021-04-08 2021-09-28 广东创晟控股集团有限公司 一种快速检测病毒的试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU2003263853A1 (en) * 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
NZ592036A (en) 2008-10-22 2012-12-21 Inst Research In Biomedicine Methods for producing antibodies from plasma cells
AU2014227909C1 (en) * 2013-03-15 2021-11-25 Dana-Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
EP3426292A1 (en) 2016-03-11 2019-01-16 THE UNITED STATES OF AMERICA, represented by the S Live attenuated zika virus vaccine
US20170298119A1 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
JP7216705B2 (ja) 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法

Also Published As

Publication number Publication date
SG11201809879WA (en) 2018-12-28
CL2021002994A1 (es) 2022-09-09
KR102595764B1 (ko) 2023-10-30
US11912757B2 (en) 2024-02-27
JP7252888B2 (ja) 2023-04-05
US11117954B2 (en) 2021-09-14
US20210355198A1 (en) 2021-11-18
ES2959883T3 (es) 2024-02-28
FI3484915T3 (fi) 2023-11-15
DOP2019000006A (es) 2019-03-31
ECSP19009170A (es) 2019-02-28
MY190553A (en) 2022-04-27
WO2018011283A1 (en) 2018-01-18
EP3484915B1 (en) 2023-08-16
MX2019000526A (es) 2019-05-02
HRP20231196T1 (hr) 2024-01-19
CN109563157B (zh) 2023-01-17
AU2017297757A1 (en) 2018-11-22
PL3484915T3 (pl) 2024-03-25
KR20190027382A (ko) 2019-03-14
LT3484915T (lt) 2023-10-10
US20210363227A1 (en) 2021-11-25
PH12018502348A1 (en) 2019-03-25
DK3484915T3 (da) 2023-10-09
EP3484915A1 (en) 2019-05-22
HUE063272T2 (hu) 2024-01-28
EP4342911A1 (en) 2024-03-27
CA3024374A1 (en) 2018-01-18
CR20190066A (es) 2019-09-10
SI3484915T1 (sl) 2024-02-29
IL262710A (en) 2018-12-31
WO2018010789A1 (en) 2018-01-18
JP2023062036A (ja) 2023-05-02
US20190256582A1 (en) 2019-08-22
DOP2021000026A (es) 2021-07-30
ZA201807467B (en) 2024-04-24
EA201990243A1 (ru) 2019-07-31
UA126381C2 (uk) 2022-09-28
CO2019001111A2 (es) 2019-08-20
JP2019533425A (ja) 2019-11-21
BR112018074456A2 (pt) 2019-03-19
IL262710B1 (en) 2024-01-01
CN109563157A (zh) 2019-04-02
CN116199775A (zh) 2023-06-02
PE20190398A1 (es) 2019-03-13

Similar Documents

Publication Publication Date Title
CL2019000067A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
CL2016003040A1 (es) Moléculas de unión tri-específicas y métodos de uso de las mismas.
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
CL2018001141A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano.
CL2017001217A1 (es) Conjugados de droga de anticuerpos.
PE20240111A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
PE20170288A1 (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno
CO2020002060A2 (es) Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
BR112013029550A2 (pt) Anticorpos neutralizantes de vírus de imunodeficiência humana e métodos de uso dos mesmos
BR112019005726A8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd27 humano, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou de um fragmento de ligação ao antígeno, de tratamento de câncer e de tratamento de uma infecção ou de uma doença infecciosa, e, uso do anticorpo ou do fragmento de ligação ao antígeno
EA202191751A1 (ru) Гуманизированное антитело против pd-1 человека
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20161210A1 (es) Anticuerpos anti-mcam y metodos de uso asociados
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
PH12017500722A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora